Planning Your Lu-177 PSMA Treatment Cycle in India: A Medical Preparation and Travel Guide for International Patients

You Have mCRPC and Are Exploring Treatment in India

Metastatic castration-resistant prostate cancer (mCRPC) is a stage of prostate cancer where the disease has spread beyond the prostate and no longer responds to standard hormone-lowering therapies. If you are at this stage, your oncologist may have discussed Lu-177 PSMA therapy as a possible next step. If cost or access is a barrier in your home country, India may have come up in your research.

This guide is written for international patients from the United Kingdom, United States, Australia, Canada, Germany, France, the UAE, and elsewhere who are seriously considering Lu-177 PSMA treatment in India. It explains the therapy in plain language and walks you through what you need medically and what each visit involves.

Planning before you travel matters. This is not a single appointment. It is a multi-cycle treatment that requires preparation and coordination between your care team in India and your oncologist at home.

What Is Lu-177 PSMA Therapy and How Does It Work?

Lu-177 PSMA therapy is a type of targeted radiation treatment. It is sometimes called radioligand therapy or radiopharmaceutical therapy.

Most prostate cancer cells carry a protein on their surface called PSMA (prostate-specific membrane antigen). In advanced prostate cancer, PSMA appears in very high amounts. Lu-177 PSMA therapy uses a molecule designed to seek out and attach to PSMA-positive cancer cells. That molecule is linked to lutetium-177, a radioactive element. Once the molecule attaches to a cancer cell, the lutetium-177 delivers a focused dose of radiation directly to it.

Because radiation comes from inside the cancer cell, nearby healthy tissue gets far less exposure than with external radiotherapy. This targeted approach differs from conventional radiation.

According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), treatment typically involves up to six cycles, with each infusion taking about one to two hours.

Who May Benefit from This Treatment?

Not every man with prostate cancer will be a candidate. Lu-177 PSMA therapy is designed for men with mCRPC whose cancer is PSMA-positive on imaging. Research suggests this treatment may help men who:

• Have metastatic castration-resistant prostate cancer
• Have PSMA-positive cancer confirmed on a Ga-68 PSMA PET/CT scan
• Have already tried at least one androgen receptor pathway inhibitor, such as enzalutamide or abiraterone
• Have adequate kidney function and blood counts
• Are mobile and functional enough to tolerate intravenous treatment (ECOG performance score 0 to 2)

Whether to use Lu-177 PSMA before or after chemotherapy is still being studied. If your oncologist has recommended chemotherapy first, it may be worth getting a specialist perspective on that sequencing decision. Our article on whether a second opinion on treatment sequencing makes sense when chemotherapy is recommended before Lu-177 PSMA explores this question in depth.

Eligibility Requirements: What Your Medical Records Need to Show

Before any Indian nuclear medicine centre can begin your treatment, they will review your medical records carefully. Here is what they are looking for.

Ga-68 PSMA PET/CT scan: This is the most important document. It confirms whether your cancer cells have enough PSMA for the therapy to work. The scan must show PSMA uptake in tumours is clearly higher than in healthy liver. Without it, treatment usually won't go forward.

Blood work: Published eligibility guidance for Lu-177 PSMA therapy indicates that most programmes require haemoglobin of at least 9 to 10 g/dL, a white blood cell count above 2,500 to 3,000 per microlitre, and platelets above 75,000 to 100,000 per microlitre. These thresholds are checked before every cycle, not just the first.

Kidney function: Lutetium-177 clears mainly through the kidneys, so you need adequate kidney function for safety. Most centres check your estimated glomerular filtration rate (eGFR) above 50 mL/min/1.73m², measured through a creatinine blood test or renal scintigraphy scan.

Performance status: The ECOG scale rates how well you can do daily activities (0 to 4). Most programmes require an ECOG score of 0, 1, or 2. This means you may have some symptoms, but you remain fairly functional.

Prior treatment history: Documentation of at least one prior androgen receptor pathway inhibitor is a standard requirement. Records of any prior chemotherapy or radiation are also reviewed to understand your full disease history.

If you're unsure whether your current records meet these requirements, ask for a remote eligibility review before booking travel. Our full guide on eligibility for Lu-177 PSMA therapy in men with mCRPC walks through each criterion in plain language.

The Treatment Process: Cycle by Cycle

Understanding the treatment schedule helps you plan your time in India between cycles.

Total cycles: Most treatment plans involve four to six cycles of Lu-177 PSMA-617. The exact number depends on how your body responds and how your medical team assesses your progress after each round.

Time between cycles: Each cycle is typically spaced six to eight weeks apart. A four-cycle course takes roughly 24 to 32 weeks total.

On treatment day: Arrive for blood tests first. Once results are ready, staff prepare and give you the infusion intravenously over about 30 to 60 minutes. You stay in a monitored area for several hours as the radiation starts to work. Most patients go home the same day.

Post-therapy scan: After each cycle, staff usually perform a post-therapy imaging scan (typically a SPECT/CT). This shows where the compound has distributed and helps the team assess early response to treatment.

Between cycles at home: You do not need to remain in India between cycles. Most international patients return home and complete blood tests locally as directed by their Indian care team, sharing results remotely before the next visit is confirmed.

What the Clinical Evidence Shows

The VISION trial was the key Phase 3 study that established Lu-177 PSMA-617 as an approved treatment for mCRPC. The trial included 831 men with PSMA-positive mCRPC who had received prior hormone therapy and taxane-based chemotherapy.

The Phase 3 VISION safety analysis showed that men who received Lu-177 PSMA-617 plus standard care had a median overall survival of 15.3 months, compared to 11.3 months in the control group. Radiographic progression-free survival also improved significantly, with a hazard ratio of 0.40. This means cancer was 60% less likely to progress in a given time period for the treated group.

Quality-of-life findings from the VISION trial showed that men receiving Lu-177 PSMA-617 reported meaningful reductions in pain and better health-related quality-of-life scores compared to those receiving standard care alone. For men with bone metastases, pain relief is often the most important benefit of this treatment.

The FDA approved Lu-177 PSMA-617 (branded as Pluvicto) in 2022, and the European Medicines Agency followed with its own approval. Research continues into earlier use, including before chemotherapy, in active clinical trials.

Expected Benefits and Limitations

Understanding what this treatment can and cannot do helps you set realistic expectations before committing to travel and treatment cycles.

Possible benefits include:

• Slowing cancer growth or spread
• Reduced PSA in many patients
• Reduced bone pain from metastases
• Better quality of life

Important limitations to understand:

• This is not a cure. The goal is to control the disease and improve quality of life.
• Not all patients respond, and response varies by tumour type
• Low or mixed PSMA expression on the scan may make it less effective
• Benefits may not last, and cancer may eventually return
• The treatment requires multiple trips and regular checkups

Side Effects and Radiation Safety After Each Cycle

Lu-177 PSMA therapy usually has side effects that are manageable in the right patients. Knowing what to expect helps you prepare.

Common side effects include:

• Fatigue, often mild to moderate, most noticeable in the days after each infusion
• Dry mouth (called xerostomia), because salivary glands absorb some of the compound
• Nausea, usually short-lived and manageable with antiemetic medication
• Reduced blood counts (anaemia, low platelets, low white cells), checked before each cycle
• Mild kidney strain, tracked through regular eGFR and creatinine testing throughout the course

Serious side effects are less common unless you already have kidney or bone marrow problems. This is why eligibility screening matters.

Radiation safety precautions after each infusion are a key part of your preparation as an international patient. Clinical best-practice guidelines for radiation safety during Lu-177 therapy recommend that patients:

• Stay more than one metre from other adults for about two days after each infusion
• Stay away from children and pregnant people for up to seven days
• Sleep alone for about seven days after each cycle
• Flush the toilet twice and wash your hands during the first week
• Follow all written radiation safety instructions from your treating centre

These precautions are short-term and protect your family from radiation exposure. Your care team will provide a written safety sheet to take home. For more on side effects and how to manage them, see our full guide on the real-world side effects of Lu-177 PSMA therapy and how they are managed.

What International Patients Should Expect: A Practical Travel Guide

Planning treatment in another country is more than just medical. Here is what to prepare before, during, and after each cycle in India.

Before You Travel: Documents to Prepare

Most Indian nuclear medicine centres now offer telemedicine pre-assessment. Before you book flights, gather and send these records:

• Ga-68 PSMA PET/CT scan (digital file and written report)
• All prior imaging: CT scans, bone scans, MRI reports
• Histopathology (biopsy) report from your original prostate cancer diagnosis
• Full treatment history: every hormone therapy, chemotherapy, and radiation course you have had
• Recent blood results: PSA, full blood count, creatinine, and liver function tests
• A clinical summary letter from your current oncologist

Send these before your flight so the Indian team can confirm your eligibility, find any gaps, and save time on arrival.

Planning Each Visit Around Your Cycle Schedule

For a typical four-cycle course, each visit usually looks like this:

• Arrival: Two to three days before treatment to rest, meet with the team, and get blood tests done
• Treatment day: A full-day visit (expect six to eight hours for setup, infusion, monitoring, and a follow-up scan)
• Recovery days: One to two days in India before flying home for the radiation to clear
• Total per cycle visit: Approximately four to six days in India
• Between cycles: Go home, get blood tests locally, and send results to the Indian team via telemedicine or patient navigator contact

Accommodation, Transfers, and Local Support

Major cities with this treatment (Mumbai, Chennai, Hyderabad, Delhi, Bangalore) have international hotels near leading nuclear medicine centres. Most large hospitals have international patient services to help with hotels, transfers, translation, and scheduling.

If you're traveling from Australia, the UK, or North America, arrive one day early. Arriving rested helps you feel better for your appointments and treatment.

Flying Home After an Infusion: What to Know

Most international patients worry about flying home shortly after an infusion. In most cases, patients can fly commercially one to two days after treatment, once radiation levels drop. Your care team will give you written guidance and a medical letter for airport security.

Airport radiation detectors may pick up residual lutetium-177 for several days after treatment. Keep your medical letter in hand luggage to show at security.

Staying Connected With Your Home Oncologist

Your home oncologist stays involved in your care. Share all cycle summaries, scan reports, and blood results with them after each visit. If you have new or worsening symptoms between cycles (like unusual fatigue, signs of infection, bone pain, or bruising), contact your local team right away. Do not wait for your next India visit.

Next Steps: Submit Your Records for a Specialist Review

If you have mCRPC and are considering Lu-177 PSMA therapy in India, the first step is to have your records reviewed before booking travel. A remote review will confirm your eligibility, find any missing documents, and show you what your treatment plan will involve.

To request a review, submit the following:

• Ga-68 PSMA PET/CT scan and written report
• Prior imaging reports (CT, bone scan, MRI)
• Histopathology report
• Full treatment history
• Recent blood results (PSA, full blood count, creatinine, liver function)

A patient navigator will review your records and explain your eligibility, costs, and next steps.

When to Talk to Your Doctor

Talk to your oncologist or nuclear medicine doctor before you book travel. Ask about your PSMA scan results, kidney function, and ability to handle treatment. A telemedicine assessment with an Indian specialist will help you understand your options.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.